Sergio E Trevino1, Hilary M Babcock1, Jeffrey P Henderson1, Michael A Lane1, Susan E Beekmann2, Philip M Polgreen2, Jonas Marschall3. 1. Division of Infectious Diseases, Washington University School of Medicine, 660 S. Euclid, St Louis, MO 63110, USA. 2. Emerging Infections Network, Carver College of Medicine, University of Iowa, 200 Hawkins Dr. SW-34JGH, Iowa City, IA 52242, USA. 3. Division of Infectious Diseases, Washington University School of Medicine, 660 S. Euclid, St Louis, MO 63110, USA Department of Infectious Diseases, Inselspital, Bern University Hospital, Friedbühlstrasse 51, Bern 3010, Switzerland jonas.marschall@insel.ch.
Abstract
OBJECTIVES: The objective of this study was to attain a better understanding of infectious diseases (ID) physicians' experience with MDR organism (MDRO) urinary tract infections (UTIs) by means of a survey on disease perception, diagnostic management and treatment preferences. METHODS: A nine-question survey was developed and distributed to members of the North American Emerging Infections Network (EIN) in September 2013. RESULTS: Seven hundred and fourteen out of 1461 EIN members responded to the survey (49%). The responses of 603 responders were studied. Most providers perceived an increase in the incidence of MDRO UTIs over the past 3 years (75% of adult ID responders and 63% of paediatric ID responders). One hundred and thirty-four (22%) responders prefer intravenous over oral administration of antimicrobials when both are available, 171 (28%) prefer longer durations of therapy when comparing an MDRO with a susceptible isolate of the same species and 142 (24%) order a repeat urine culture as 'proof of cure' after treating an MDRO UTI. Nevertheless, 530 (88%) responders perceived MDRO UTIs to be of similar severity as non-MDRO UTIs. Fifty-five percent of providers prescribed fosfomycin for MDRO UTI at least once; the most common prescribing pattern (among a wide spectrum of approaches) was a single dose (16%). CONCLUSIONS: Future studies on MDRO UTIs should clarify the role of resistance in patient outcomes and the comparative efficacy of different antimicrobials. Of particular interest is fosfomycin, which is unrelated to other antibiotic classes and may take a more prominent role in treating MDRO cystitis.
OBJECTIVES: The objective of this study was to attain a better understanding of infectious diseases (ID) physicians' experience with MDR organism (MDRO) urinary tract infections (UTIs) by means of a survey on disease perception, diagnostic management and treatment preferences. METHODS: A nine-question survey was developed and distributed to members of the North American Emerging Infections Network (EIN) in September 2013. RESULTS: Seven hundred and fourteen out of 1461 EIN members responded to the survey (49%). The responses of 603 responders were studied. Most providers perceived an increase in the incidence of MDRO UTIs over the past 3 years (75% of adult ID responders and 63% of paediatric ID responders). One hundred and thirty-four (22%) responders prefer intravenous over oral administration of antimicrobials when both are available, 171 (28%) prefer longer durations of therapy when comparing an MDRO with a susceptible isolate of the same species and 142 (24%) order a repeat urine culture as 'proof of cure' after treating an MDRO UTI. Nevertheless, 530 (88%) responders perceived MDRO UTIs to be of similar severity as non-MDRO UTIs. Fifty-five percent of providers prescribed fosfomycin for MDRO UTI at least once; the most common prescribing pattern (among a wide spectrum of approaches) was a single dose (16%). CONCLUSIONS: Future studies on MDRO UTIs should clarify the role of resistance in patient outcomes and the comparative efficacy of different antimicrobials. Of particular interest is fosfomycin, which is unrelated to other antibiotic classes and may take a more prominent role in treating MDRO cystitis.
Authors: Frédéric Garcin; Marc Leone; François Antonini; Aude Charvet; Jacques Albanèse; Claude Martin Journal: Intensive Care Med Date: 2009-09-24 Impact factor: 17.440
Authors: Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual Journal: Arch Intern Med Date: 2008-09-22
Authors: José A Vazquez; Luis Demetrio González Patzán; David Stricklin; Dipesh D Duttaroy; Zouheir Kreidly; Joy Lipka; Carole Sable Journal: Curr Med Res Opin Date: 2012-11-21 Impact factor: 2.580
Authors: L B J van der Velden; M Tromp; C P Bleeker-Rovers; M Hulscher; B J Kullberg; J W Mouton; P D J Sturm; P Pickkers Journal: Eur J Clin Microbiol Infect Dis Date: 2011-11-23 Impact factor: 3.267
Authors: Iain J Abbott; Elke van Gorp; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: Courtney M Starks; Michelle M Miller; Peter M Broglie; Joshua Cubbison; Steven M Martin; Gary R Eldridge Journal: Hum Vaccin Immunother Date: 2020-07-23 Impact factor: 3.452
Authors: Robin M E Janssen; Anke J M Oerlemans; Johannes G Van Der Hoeven; Jaap Ten Oever; Jeroen A Schouten; Marlies E J L Hulscher Journal: J Antimicrob Chemother Date: 2022-07-28 Impact factor: 5.758